Sobuzoxane

Sobuzoxane (MST-16) is an orally active topoisomerase II inhibitor. Sobuzoxane causes irreversible inhibition of cell division. Sobuzoxane can be used in the study of non-Hodgkin's lymphoma that is resistant to conventional chemotherapy or has recurred[1].

Product Specifications

CAS Number

[98631-95-9]

Product Name Alternative

MST 16

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Topoisomerase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sobuzoxane.html

Purity

98.05

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)COC(OCN1C(CN(CCN(C2)CC(N(COC(OCC(C)C)=O)C2=O)=O)CC1=O)=O)=O

Molecular Formula

C22H34N4O10

Molecular Weight

514.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Okamoto T, et al. Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin’s lymphoma[J]. Acta Haematologica, 2001, 104 (2-3) : 128-130.